casdozokitug + toripalimab + bevacizumab

This is a combination regimen comprising **casdozokitug**, **toripalimab**, and **bevacizumab**. - **Casdozokitug** is a novel biologic; the precise modality and mechanism appear to be under investigation, likely in the context of cancer immunotherapy or targeted therapy. - **Toripalimab** is a monoclonal antibody targeting the PD-1 receptor, acting as an immune checkpoint inhibitor to block PD-1 interactions with PD-L1 and PD-L2, thus boosting antitumor immune responses. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby suppressing tumor neovascularization. This combination is currently being evaluated in clinical trials, particularly for advanced or unresectable hepatocellular carcinoma and other solid tumors, as part of immunotherapy plus anti-angiogenesis strategies[4][1].

Brand names

TUOYI

Other names

casdozokitugJS001 (toripalimab)bevacizumab